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COMMENTARY
Splicing of the cake can affect
the severity of epidermolysis
bullosa
A detailed understanding of genetics is important for dermatolo-
gists to appreciate the variability in severity of their patients’ dis-
eases, not only in complex polygenic disorders such as skin
cancers, but also in rare single-gene syndromes. In general, how
much normal functional protein is remaining as a result of the
mutations can be related to the severity of the patient’s clinical
appearance. In most cases of single-gene disorders, the types of
mutation(s) determine the amount of functional protein. In a
broad sense, there are three types of mutations: the good, the
bad and the ugly. Relatively speaking, the ‘good’ ones lead to
milder disease, often as a result of single base-pair substitutions,
where an amino acid is substituted by another, resulting in a
dominant-negative effect in autosomal dominant conditions,
such as epidermolysis bullosa (EB) simplex or dominant dys-
trophic EB. The ‘ugly’ mutations include those in which no
functional protein is being made – examples include premature
termination codons, or ‘PTC’s’, which cause a stop of translation
and no full-length protein being made, such as in many cases
with severe recessive forms of EB. The ‘bad’ mutations cause a
disease of intermediate severity and are often ‘splicing’ muta-
tions – i.e. nucleotide substitutions at the exon/intron borders
affecting DNA sequences critical for canonical splicing, i.e.
removal of introns and linking adjacent exons. In the case of
splicing mutations, sometimes one or more exons can be
skipped, and the affected exon can join up again ‘in-frame’ with
another exon further down the length of the gene, thus splicing
out variable exons in-between. These events of aberrant splicing
result in synthesis of proteins that are shorter than the original
protein, thus resulting in structure, or ‘cake’, that has had some
slices removed. The clinical features, or the ‘phenotype’, of these
splice variants can vary a lot, as for example, between localized
milder and generalized severe recessive forms of EB.
In addition to these mechanisms, in some families with reces-
sive forms of EB, the children who all have the same two muta-
tions, or the ‘genotype’, can on occasion have vastly different
phenotypes. Sometimes, one of them improves with age whilst
the other does not, as reported in this issue by Mittwollen et al.1
of two siblings, a male and a female, with junctional EB (JEB)
caused by LAMB3 gene mutations. JEB may be caused by muta-
tions in up to six different genes, but more than 50% of them
are caused by ‘hotspot’ mutations in the LAMB3 gene,2 which
encodes one of the three subunit polypeptides of Laminin 332.
This protein makes up anchoring filaments, important attach-
ment structures which are like velcro, sticking the basal cells of
the epidermis into the underlying dermo-epidermal basement
membrane.
In the family reported by Mittwollen et al., both siblings had
one ‘ugly’ hotspot PTC mutation in LAMB3, p.Arg635X, whilst
the second mutation was supposed to be a relatively ‘good’ one,
c.628G>A, predicting an amino acid substitution, p.Glu210Lys,
and a generalized intermediate JEB phenotype.1,3 However, this
mutation resides at the end of exon 7 at the exon 7/intron 7 bor-
der, and can therefore affect splicing, being in fact a ‘bad’ muta-
tion. The brother in this family improved dramatically after the
age of 6 years, whilst his younger sister continued to deteriorate.
Biopsies of their skin in their mid-20s to study the splicing of
LAMB3 found that each of them had many different splicing
variants, but the brother, who was mildly affected and able to
live independently and hold down a job, had many more full-
length splice variants than his much more severely affected sister.
Why this difference in the splicing pattern happened remains
unclear, but spliceosomes are dynamic macromolecular com-
plexes composed of small nuclear RNAs and proteins whose
proper interactions are critical for physiological splicing.4,5
Intriguingly, the brother with the milder phenotype was trea-
ted at age 21 with oral ivermectin after contracting scabies and
his EB becoming worse. Following treatment with ivermectin,
his EB returned to baseline. We previously reported a patient
with dominant dystrophic EB whose blistering became much
worse after endemic scabies epidemics, but following eradication
with repeated courses of ivermectin, his blistering drastically
improved.6 We assumed that this was related to improved
hygiene after this patient was incarcerated or possibly to reduced
itching after eradication of the scabies infection.
Interestingly, it turns out that ivermectin interferes with vari-
ous pathways which affect RNA synthesis, including interacting
with various epigenetic regulators such as RNA helicase 1,
SIN3A and SIN3B, chloride channel receptors, purigenic recep-
tors and signalling pathways, and even stem cell populations,
such that ivermectin is being potentially repurposed as an anti-
tumour therapy.7 As the reason for phenotypic severity differ-
ences was found in differential splicing patterns between these
two siblings, it would be interesting to study the effects of iver-
mectin on splicing in patients with EB.
Why is this important? Firstly, the genetic mutation informa-
tion will help to predict the phenotype to some extent, but is not
always predictive, as in this family, and determination of the
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levels of functional protein in the skin from biopsies should be
helpful. Secondly, while treatments under development for
genetic conditions, such as EB, include drugs which facilitate
read-through of PTC mutations or allow skipping of exons con-
taining the pathogenic mutations, better understanding of how
to induce full-length protein variants from splice mutations,
instead of deletion of large splices, could benefit patients with
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